Elicio Therapeutics Inc. (ELTX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Elicio Therapeutics Inc. (NASDAQ: ELTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.75 (-5.40% 1D, market cap $47.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ELTX ranks #855 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELTX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SER (Serina Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $48.0M) and ATNM (Actinium Pharmaceuticals Inc. (Delaware)) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $48.1M). Among the 5-stock peer group, ELTX leads on earnings multiple (N/A) while ELTX leads on capital efficiency (-35.0% ROIC).
Per ELTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601485), Elicio Therapeutics Inc. generated $0 in revenue, -$39.6M in net income, and -$37.0M in free cash flow against $25.9M in total assets and $9.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ELTX currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.04) and Max Pain ($1.84) forces dealer call-delta covering toward $16.80.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Elicio Therapeutics Inc. (ELTX) dropped -5.40% to $1.75, trading at 2% of its 52-week range ($1.44 – $16). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Keynote/plenary session and late-breaking poster presentation highlight additional data from Phase 2 AMPLIFY-7P trial of camupepimut (ELI-002 7P) in KRAS-mutated pancreatic cancerAdditional preclinical poster presentatio
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the
Multiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P), including patients with and without detectable baseline ctDNA.Encouraging disease-free survival outcomes were observed in both ctDNA-negative (HR
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics (NASDAQ:AARD) stock
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Elicio Therapeutics Inc. (ELTX) ranks #855 by composite RQD confidence (30/100, grade E) and #758 by equity capitalization ($47.4M). Within this direct 5-issuer industry benchmark cohort, ELTX leads on earnings valuation at N/A trailing P/E, while ELTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATNM currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with ELTX at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELTX
ACTIVE
Elicio Therapeutics Inc. | E | 30/100 | — | — | -35.0% | -5.40% | $47.4M | Benchmark Subject |
| SER Serina Therapeutics Inc. | E | 31/100 | — | — | -35.0% | +15.24% | $48.0M | /ser-vs-eltx → |
| ATNM Actinium Pharmaceuticals Inc. (Delaware) | D | 44/100 | — | — | -35.0% | +10.87% | $48.1M | /atnm-vs-eltx → |
| MREO Mereo BioPharma Group plc | D- | 39/100 | — | — | -35.0% | +1.62% | $48.2M | /mreo-vs-eltx → |
| CTOR Citius Oncology Inc. | E | 34/100 | — | — | -35.0% | -8.20% | $49.2M | /ctor-vs-eltx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elicio Therapeutics Inc. (ELTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$39.6M, operating cash flow of -$37.0M, and free cash flow of -$37.0M (+0.5% YoY). On the balance sheet, ELTX closed FY2025 with $25.9M in total assets against $9.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$39.6M | -$37.0M | -$37.0M | $25.9M | $9.4M |
| FY2024 (FY) | 2024-12-31 | $0 | -$51.9M | -$37.1M | -$37.2M | $28.2M | $20.0M |
| FY2023 (FY) | 2023-12-31 | $0 | -$35.2M | -$32.7M | -$32.7M | — | — |
As of 2026-11-02, Elicio Therapeutics Inc. (NASDAQ: ELTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.75 (-5.40% 1D, market cap $47.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ELTX ranks #855 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELTX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SER (Serina Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $48.0M) and ATNM (Actinium Pharmaceuticals Inc. (Delaware)) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $48.1M). Among the 5-stock peer group, ELTX leads on earnings multiple (N/A) while ELTX leads on capital efficiency (-35.0% ROIC).
Per ELTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601485), Elicio Therapeutics Inc. generated $0 in revenue, -$39.6M in net income, and -$37.0M in free cash flow against $25.9M in total assets and $9.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ELTX last traded at $1.75 (-5.40% on volume of 135,957 shares), positioning the stock -14.22% below its 50-day simple moving average ($2.04) and -74.07% below its 200-day simple moving average ($6.75). Across its 52-week range of $1.44 to $16.00, ELTX sits at the 2.1% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.53 to $1.97).
Why ELTX Stock dropped -5.40% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).